FDAapproval72% confidence
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
Source: FDA
Why This Matters
Why this matters: sets a approval precedent in the same sub-indication (breast cancer) as AstraZeneca.
Regulatory Analysis
FDA does not issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer to Drugs@FDA for the latest approvals and prescribing information for specific products.
Supporting Context
- Therapeutic area
- Oncology · ADC
- Sub-indication
- Breast Cancer
Related signal: Datroway approved in US as first TROP2-directed ADC for 1L triple-negative breast cancer